Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 3interventionalRules rewrite

Phase 3: testing Arm A: Belantamab Mafodotin for Multiple Myeloma

Eligible participants with newly diagnosed myeloma who are not considered eligible or refuse bone marrow transplant will be enrolled. you would be randomly assigned to either belantamab mafodotin or daratumumab given in combination with bortezomib, lenalidomide and dexamethasone.

Official registry: https://clinicaltrials.gov/study/NCT07285239 · PrECOG, LLC. · enrollment listed as 500

What this phase means

Phase 3: this treatment already looked useful in smaller studies. Now it is tested in a large group, often against standard care or a dummy treatment, to see if it should be approved.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Arm A: Belantamab Mafodotin, Arm B: Daratumumab Hyaluronidase, or Bortezomib. The registry lists allocation as randomized. Eligible participants with newly diagnosed myeloma who are not considered eligible or refuse bone marrow transplant will be enrolled.

They plan to enroll about 500 people at La Crosse. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

Randomized Phase 3 Trial of Belantamab Mafodotin or Daratumumab in Combination With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Interventions: Arm A: Belantamab Mafodotin, Arm B: Daratumumab Hyaluronidase, Bortezomib, Lenalidomide, Dexamethasone

Primary outcome (registry wording): MRD Negative Status

Who it is for (from inclusion criteria)

  • Ages 18 Years to 79 Years
  • Eligibility Criteria:
  • Patient must have suspected or confirmed newly diagnosed multiple myeloma (MM) by International Myeloma Working Group (IMWG) criteria and must not have received more than one cycle of any myeloma treatment
  • Patient must have measurable or evaluable disease as defined by having one or more of the following, obtained within 28 days prior to randomization
  • ≥ 1g/dL monoclonal protein (M-protein) on serum protein electrophoresis
  • Involved free light chain ≥ 10 mg/dL or ≥ 100 mg/L AND abnormal serum immunoglobulin kappa to lambda free light chain ratio (\<0.26 or \>1.65)
  • ≥ 200 mg/24 hours of monoclonal protein on a 24-hour urine protein electrophoresis
  • Monoclonal bone marrow plasmacytosis ≥ 30% (evaluable disease)

Public study contact (from the registry)

Michael Wright, MS

267-319-3910

PrE1005@precogllc.org

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingPhase 1La Jolla, California
Phase 1: testing Linvoseltamab for Multiple Myeloma

This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again.

NCT05137054 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals

FAQ about this NCT record

Is NCT07285239 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07285239?

Phase 3. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07285239?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary